Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluación de un suplemento capilar oral para mejorar la fuerza del cabello y favorecer el crecimiento en mujeres y hombres

10 de noviembre de 2026 actualizado por: Nutraceutical Wellness Inc.

A Single-Center Prospective Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men With Self-Perceived Hair Thinning

A single-center, open-label, prospective study to demonstrate the efficacy of an oral supplement to improve the strength and support the growth of thinning hair in men and women with self-perceived hair thinning.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Female and male subjects will be enrolled in this single-site, open-label, prospective, interventional study evaluating 5 treatment regimens to improve the appearance of thinning hair. All treatment regimens are commercially available nutraceutical hair growth supplements. 50 subjects will be enrolled into each of the 5 supplement groups. Subjects will undergo a baseline, 90 day, and 180 day visit and will have compliance phone calls at Days 45 and 135. Study assessments will include a dermatologist investigator hair assessment, a hair pull test, light microscope hair shaft diameter assessment, and a subject questionnaire.

Tipo de estudio

Intervencionista

Inscripción (Actual)

250

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • North Carolina
      • High Point, North Carolina, Estados Unidos, 27262
        • Dermatology Consulting Services

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Female or male subjects with concerns and/or signs of hair thinning.
  2. The subjects must meet the age characteristics based on their supplement group assignment.
  3. Subjects are Fitzpatrick Skin Types I to VI.
  4. Subjects must be in good general health.
  5. Subjects must be classified with thinning hair by the study dermatologist.
  6. Willing to maintain the same hair length, hairstyle, and coloring practices for the duration of the study. Subjects who have color-treated hair must have the color treatment performed at the same time interval prior to each visit.
  7. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
  8. Willing and able to adhere to the same dietary lifestyles for the duration of the study
  9. Subjects must express willingness to cooperate with the investigator and comply to study requirements.
  10. Subjects must demonstrate the ability to read and understand all the items in the informed consent document.
  11. Subjects must agree not to use any other hair supplements or start a new vitamin supplement during the study.
  12. Subject has signed an Informed Consent Form in compliance with 21CFR Part 50: "Protection of Human Subjects."
  13. Subject is dependable and able to follow directions and is willing to comply with the schedule of visits.

Exclusion Criteria:

  1. Any previous or current acute or chronic medical or hair condition, which in the investigator's opinion, may interfere with the study results or increase the study participation risks to the subject.
  2. Subjects possessing signs of severe female or male pattern hair loss or alopecia (including androgenetic and traction alopecia) as determined by the study dermatologist.
  3. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  4. Subjects who are not willing to use only the assigned oral study supplement and no new oral supplements during the study.
  5. Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study product.
  6. Subjects, who are pregnant, breast feeding, or planning a pregnancy.
  7. Subjects with clinically significant unstable medical disorders.
  8. Subjects who are unwilling or unable to comply with the requirements of the protocol.
  9. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and/or follow the requirements of the study.
  10. Subjects with any planned surgeries and/or invasive medical procedures during the course of the study.
  11. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
  12. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
  13. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  14. hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
  15. History of burning, flaking, itching, and stinging of the scalp.
  16. Utilization of low-level lasers for hair growth in the last three months.
  17. Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day.
  18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Nutrafol Hair Growth Supplement

5 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.

Hair growth supplement for women ages 18 - 44.

Hair growth supplement for women ages 45 - 70.

Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.

Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Hair growth supplement for men ages 25 - 50.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in hair shaft diameter compared to baseline at Day 180.
Periodo de tiempo: 180 days

The ability of an oral supplement to improve hair shaft strength as evidenced by change in hair shaft diameter from baseline at Day 180 in new scalp hair growth as viewed by the study dermatologist under a light microscope in men and women with self-perceived thinning hair.

180 days
Change in hair shaft diameter compared to baseline at Day 90.
Periodo de tiempo: 90 days

The ability of an oral supplement to improve hair shaft strength as evidenced by change in hair shaft diameter from baseline at Day 90 in new scalp hair growth as viewed by the study dermatologist under a light microscope in men and women with self-perceived thinning hair.

90 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in broken hairs recovered from the hair pull test compared to baseline at Day 180
Periodo de tiempo: 180 days

The ability of an oral supplement to improve hair strength as evidenced by a change in the number of broken hairs recovered from the hair pull test at Day 180 compared to baseline in men and women with self-perceived thinning hair.

180 days
Change in broken hairs recovered from the hair pull test compared to baseline at Day 90
Periodo de tiempo: 90 days

The ability of an oral supplement to improve hair strength as evidenced by a change in the number of broken hairs recovered from the hair pull test at Day 90 compared to baseline in men and women with self-perceived thinning hair.

90 days
Change in hair breakage during the hair pull test compared to baseline at Day 180
Periodo de tiempo: 180 Days

The ability of an oral supplement to promote longer hair as evidenced by change in hair breakage observed in the hair pull test compared to baseline at Day 180.

180 Days
Change in hair breakage during the hair pull test compared to baseline at Day 90
Periodo de tiempo: 90 Days

The ability of an oral supplement to promote longer hair as evidenced by change in hair breakage observed in the hair pull test compared to baseline at Day 90.

90 Days
Change in the number of hairs recovered from the hair pull test compared to baseline at Day 180
Periodo de tiempo: 180 Days

The ability of an oral supplement to improve hair shedding as evidenced by a change in the number of hairs recovered from the hair pull test compared to baseline at Day 180 in men and women with self-perceived thinning hair.

180 Days
Change in the number of hairs recovered from the hair pull test compared to baseline at Day 90
Periodo de tiempo: 90 Days

The ability of an oral supplement to improve hair shedding as evidenced by a change in the number of hairs recovered from the hair pull test compared to baseline at Day 90 in men and women with self-perceived thinning hair.

90 Days
Subject Self-Perceived Improvement in Hair Quality at Day 180
Periodo de tiempo: 180 Days

The ability of an oral supplement to improve hair growth and quality in men and women with self-perceived thinning hair as measured by self-assessment questionnaires using a 5-point ordinal scale (0=excellent, 1=good, 2=average, 3=poor, 4=very poor) at Day 180.

180 Days
Subject Self-Perceived Improvement in Hair Quality at Day 90
Periodo de tiempo: 90 Days

The ability of an oral supplement to improve hair growth and quality in men and women with self-perceived thinning hair as measured by self-assessment questionnaires using a 5-point ordinal scale (0=excellent, 1=good, 2=average, 3=poor, 4=very poor) at Day 90.

90 Days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de mayo de 2024

Finalización primaria (Actual)

18 de febrero de 2025

Finalización del estudio (Actual)

18 de febrero de 2025

Fechas de registro del estudio

Enviado por primera vez

8 de abril de 2024

Primero enviado que cumplió con los criterios de control de calidad

11 de abril de 2024

Publicado por primera vez (Actual)

12 de abril de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NW-HGN-01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .